Fredag 6 December | 20:50:22 Europe / Stockholm

Kalender

Tid*
2024-11-19 - Extra Bolagsstämma 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-29 - X-dag ordinarie utdelning ABS 0.00 NOK
2024-04-26 - Årsstämma
2024-04-09 - Bokslutskommuniké 2023
2023-09-29 - Kvartalsrapport 2023-Q2
2023-04-24 - X-dag ordinarie utdelning ABS 0.00 NOK
2023-04-21 - Årsstämma
2023-03-29 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning ABS 0.00 NOK
2022-05-05 - Årsstämma
2022-04-07 - Bokslutskommuniké 2021
2021-11-10 - Extra Bolagsstämma 2021
2021-08-26 - Kvartalsrapport 2021-Q2

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Arctic Bioscience är ett bioteknikföretag som utvecklar och kommersialiserar läkemedelsprodukter och kosttillskott baserade på bioaktiva marina råvaror. Företaget utvecklar HRO350, en ny läkemedelskandidat för behandling av patienter med mild till måttlig psoriasis. Kosttillskott säljs globalt både som bulkingredienser och som färdiga produkter under varumärket ROMEGA, till både företag och privatkunder.
2022-03-23 09:00:00

Arctic Bioscience has appointed Jone R. Slinning as the Company's new CFO. Slinning will succeed Danielle Glenn, who has accepted a position with another company.

Slinning has a broad and long experience from various industries, including auditing, the banking and finance sector, and different CFO positions. He comes from the position as CFO of Cflow Fish Handling and CFO for the consolidated Enflow Group, a company in the aquaculture industry. Slinning holds a Master of Economics degree ("siviløkonom") from Norwegian School of Economics (NHH).

"We are very pleased that Jone has accepted the position as CFO in Arctic Bioscience. With his background and experience we are sure that this will be a good match for the Company in the stage that we are in, and we are certain that Jone will complement the great team we have in Arctic Bioscience", says Christer L. Valderhaug, CEO.

"I really look forward to being a part of Arctic Bioscience and contribute with my knowledge and initiatives. The Company is in an exciting phase, both within the pharma and nutraceuticals segments, and with a strong and positive growth ambition going forward", says Slinning.

Jone R. Slinning will start in his new position 1 April 2022.